Back to Journals » OncoTargets and Therapy » Volume 9

Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors

Authors Wu X, Zhang H, Salmani JMM, Fu R, Chen B

Received 2 February 2016

Accepted for publication 31 March 2016

Published 17 May 2016 Volume 2016:9 Pages 2935—2943


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Jianmin Xu

Xue Wu,1 Haijun Zhang,2 Jumah Masoud Mohammad Salmani,1 Rong Fu,3 Baoan Chen1

1Department of Hematology, 2Department of Oncology, The Affiliated Zhongda Hospital, School of Medicine, Southeast University, 3Department of Physiology, China Pharmaceutical University, Nanjing, People’s Republic of China

Abstract: As the major bioactive compound of Scutellaria baicalensis that has been approved to be effective as an anti-inflammatory and antiviral inhibitor in cardiovascular diseases, wogonin (WG) showed potent and promising antitumor effects both in vitro and in vivo. It has been proved that WG has the ability to inhibit the growth of tumor cells, induce apoptosis, and suppress angiogenesis. The molecular mechanisms involve reactive oxygen species, Ca2+, NF-κB, tumor necrosis factor-related apoptosis-inducing ligand, and tumor necrosis factor-alpha. Furthermore, the synergistic effect of WG with 5-fluorouracil, etoposide, and adriamycin to enhance chemotherapy and reverse drug resistance has also been confirmed. In this review, we summarize the advances in recent years on the antitumor effect of WG on multiple tumors; in addition, we also present information regarding the synergistic and chemosensitizing effects of WG with other drugs to illustrate its potential use in the clinic.

Keywords: antitumor effect, drug resistance, mechanisms, synergistic effect

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]